James Trotter, MD
Gastroenterology · Murray, UTNPI 1225128903
Payments from drug & device makers
Across 279 payments — averaging $7087.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$1.1M
- Gilead$480K
- Intercept Pharma Europe Ltd.$255K
- La Jolla Pharmaceutical Company$55K
- Mallinckrodt Hospital Products Inc.$31K
- E.r. Squibb & Sons, L.L.C.$18K
- plus $28K from 9 others
What the payments were for
- Consulting fees$14,34494%
- Food & beverage$8516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 134 | $1,111,661 |
| Gilead | 68 | $479,794 |
| Intercept Pharma Europe Ltd. | 12 | $255,319 |
| La Jolla Pharmaceutical Company | 8 | $54,858 |
| Mallinckrodt Hospital Products Inc. | 3 | $30,803 |
| E.r. Squibb & Sons, L.L.C. | 3 | $17,501 |
| Mallinckrodt Enterprises LLC | 7 | $11,772 |
| AbbVie | 27 | $5,784 |
| Modernatx, Inc. | 5 | $4,284 |
| Organox Ltd | 1 | $3,000 |
| Merck | 5 | $2,550 |
| Shionogi Inc | 2 | $45 |
| Dova Pharmaceuticals | 2 | $33 |
| GI Supply, Inc. | 1 | $32 |
| Optos, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$2,060
How this compares
$1,977,451 in reported general payments places this provider in the 95th percentile of 122 gastroenterology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 25 | $88,281 |
| Mycophenolic AcidMycophenolate Sodium | 37 | $20,912 |
| Sirolimus | 21 | $16,880 |
| Ursodiol | 60 | $9,773 |
| Tacrolimus | 60 | $8,516 |
| Cyclosporine ModifiedCyclosporine, Modified | 21 | $4,394 |
| Tenofovir Disoproxil Fumarate | 13 | $2,067 |
| Azathioprine | 32 | $1,053 |
| Neomycin Sulfate | 22 | $783 |
| Spironolactone | 43 | $716 |
| Lactulose | 14 | $607 |
| Pantoprazole Sodium | 19 | $267 |
| Prednisone | 38 | $247 |
| Furosemide | 39 | $223 |
| Ciprofloxacin Hcl | 12 | $101 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Murray
- Jonathan WongMurray$7K
- Sandeep SinghMurray$5K
- John LoweOgden$3.6M
- Chad GonzalesOgden$2.9M
- John ValentineSalt Lake City$2.2M
- Kathryn PetersonSalt Lake City$1.3M
- Priyanka KanthSalt Lake City$1.3M
- Richard GilroySalt Lake City$1.1M
- Peder PedersenSalt Lake City$1M
- Robert Kyle BarnettSandy$877K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.